Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy. [Tratamiento de la leucemia mieloide aguda de novo con la combinacion de idarrubicina en dosis creciente, citarabina y sensibilizacion ("priming") con G-CSF. Estudio prospectivo en fase I/II de toxicidad y eficacia]

Next Previous
X
Search
Trial Profile

Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy. [Tratamiento de la leucemia mieloide aguda de novo con la combinacion de idarrubicina en dosis creciente, citarabina y sensibilizacion ("priming") con G-CSF. Estudio prospectivo en fase I/II de toxicidad y eficacia]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine; Granulocyte colony-stimulating factors; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Jan 2016 Biomarkers information updated
    • 03 Oct 2012 Planned end date changed from 21 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 03 Oct 2012 New source identified and integrated (NCT01700413: ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top